Do analysts rate XGN or BTMD?

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 14.45%. biote has a consensus target price of $2.50, indicating a potential upside of 83.82%. Given biote's higher possible upside, analysts clearly believe biote is more favorable than Exagen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, XGN or BTMD?

biote has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 3.06 -$19.95M -$0.81 N/A biote $192.22M 0.25 $27.05M $0.11 12.36

Is XGN or BTMD more profitable?

biote has a net margin of 3.19% compared to Exagen's net margin of -26.61%. biote's return on equity of -22.33% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% biote 3.19% -22.33% 12.10%

Does the media favor XGN or BTMD?

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.71 beat biote's score of 0.00 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, LFMD or BTMD?

biote has lower revenue, but higher earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.80 $14.35M -$0.05 N/A biote $192.22M 0.25 $27.05M $0.11 12.36

Is LFMD or BTMD more profitable?

biote has a net margin of 3.19% compared to LifeMD's net margin of 0.10%. biote's return on equity of -22.33% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% biote 3.19% -22.33% 12.10%

Does the media prefer LFMD or BTMD?

In the previous week, LifeMD had 4 more articles in the media than biote. MarketBeat recorded 5 mentions for LifeMD and 1 mentions for biote. LifeMD's average media sentiment score of 0.36 beat biote's score of 0.00 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BTMD or JYNT?

biote currently has a consensus target price of $2.50, indicating a potential upside of 83.82%. Given biote's stronger consensus rating and higher probable upside, equities research analysts plainly believe biote is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger earnings & valuation, BTMD or JYNT?

biote has higher revenue and earnings than Joint. biote is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.25 $27.05M $0.11 12.36 Joint $54.90M 2.17 $2.91M $0.27 31.26

Is BTMD or JYNT more profitable?

Joint has a net margin of 6.49% compared to biote's net margin of 3.19%. Joint's return on equity of 12.02% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets biote 3.19% -22.33% 12.10% Joint 6.49% 12.02% 3.47%

Is ACH or BTMD more profitable?

biote has a net margin of 3.19% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Accendra Health -11.41% -4.02% 0.70% biote 3.19% -22.33% 12.10%

Does the media refer more to ACH or BTMD?

In the previous week, Accendra Health had 2 more articles in the media than biote. MarketBeat recorded 3 mentions for Accendra Health and 1 mentions for biote. Accendra Health's average media sentiment score of 0.50 beat biote's score of 0.00 indicating that Accendra Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

biote (BTMD) Competitors

$1.36 +0.01 (+0.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.00 (+0.37%)

As of 09/18/2026 07:30 PM Eastern

Compare

BTMD vs. XGN, LFMD, JYNT, PARK, and ACH

Should you buy biote stock or one of its competitors? biote's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), and Accendra Health (ACH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does biote compare to Exagen?

Exagen (NASDAQ:XGN) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

biote has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A
biote	$192.22M	0.25	$27.05M	$0.11	12.36

Exagen has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, biote has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 14.45%. biote has a consensus target price of $2.50, indicating a potential upside of 83.82%. Given biote's higher possible upside, analysts clearly believe biote is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.71 beat biote's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

biote has a net margin of 3.19% compared to Exagen's net margin of -26.61%. biote's return on equity of -22.33% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
biote	3.19%	-22.33%	12.10%

75.3% of Exagen shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

biote beats Exagen on 9 of the 15 factors compared between the two stocks.

How does biote compare to LifeMD?

LifeMD (NASDAQ:LFMD) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

biote has lower revenue, but higher earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.80	$14.35M	-$0.05	N/A
biote	$192.22M	0.25	$27.05M	$0.11	12.36

In the previous week, LifeMD had 4 more articles in the media than biote. MarketBeat recorded 5 mentions for LifeMD and 1 mentions for biote. LifeMD's average media sentiment score of 0.36 beat biote's score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

biote has a net margin of 3.19% compared to LifeMD's net margin of 0.10%. biote's return on equity of -22.33% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
biote	3.19%	-22.33%	12.10%

LifeMD presently has a consensus target price of $7.57, suggesting a potential upside of 135.14%. biote has a consensus target price of $2.50, suggesting a potential upside of 83.82%. Given LifeMD's stronger consensus rating and higher possible upside, equities research analysts clearly believe LifeMD is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LifeMD has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, biote has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Summary

LifeMD beats biote on 9 of the 17 factors compared between the two stocks.

How does biote compare to Joint?

biote (NASDAQ:BTMD) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Joint has a net margin of 6.49% compared to biote's net margin of 3.19%. Joint's return on equity of 12.02% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Joint	6.49%	12.02%	3.47%

21.7% of biote shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

biote has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Joint has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

biote has higher revenue and earnings than Joint. biote is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.25	$27.05M	$0.11	12.36
Joint	$54.90M	2.17	$2.91M	$0.27	31.26

In the previous week, biote had 1 more articles in the media than Joint. MarketBeat recorded 1 mentions for biote and 0 mentions for Joint. biote's average media sentiment score of 0.00 equaled Joint'saverage media sentiment score.

Company	Overall Sentiment
biote	Neutral
Joint	Neutral

biote currently has a consensus target price of $2.50, indicating a potential upside of 83.82%. Given biote's stronger consensus rating and higher probable upside, equities research analysts plainly believe biote is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

biote beats Joint on 10 of the 16 factors compared between the two stocks.

How does biote compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Park Dental Partners presently has a consensus price target of $28.50, indicating a potential upside of 40.12%. biote has a consensus price target of $2.50, indicating a potential upside of 83.82%. Given biote's higher probable upside, analysts plainly believe biote is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, biote had 1 more articles in the media than Park Dental Partners. MarketBeat recorded 1 mentions for biote and 0 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 0.00 equaled biote'saverage media sentiment score.

Company	Overall Sentiment
Park Dental Partners	Neutral
biote	Neutral

biote has lower revenue, but higher earnings than Park Dental Partners. biote is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.40	-$360K	$1.05	19.37
biote	$192.22M	0.25	$27.05M	$0.11	12.36

21.7% of biote shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

biote has a net margin of 3.19% compared to Park Dental Partners' net margin of 0.00%. Park Dental Partners' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
biote	3.19%	-22.33%	12.10%

Summary

biote beats Park Dental Partners on 7 of the 12 factors compared between the two stocks.

How does biote compare to Accendra Health?

Accendra Health (NYSE:ACH) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Accendra Health has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, biote has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

In the previous week, Accendra Health had 2 more articles in the media than biote. MarketBeat recorded 3 mentions for Accendra Health and 1 mentions for biote. Accendra Health's average media sentiment score of 0.50 beat biote's score of 0.00 indicating that Accendra Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of biote shares are owned by institutional investors. 2.3% of Accendra Health shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Accendra Health currently has a consensus target price of $1.50, indicating a potential upside of 61.19%. biote has a consensus target price of $2.50, indicating a potential upside of 83.82%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 3.19% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
biote	3.19%	-22.33%	12.10%

biote has lower revenue, but higher earnings than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A
biote	$192.22M	0.25	$27.05M	$0.11	12.36

Summary

biote beats Accendra Health on 13 of the 17 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$48.50M	$9.80B	$7.25B	$13.14B
Dividend Yield	N/A	2.61%	2.57%	12.30%
P/E Ratio	12.36	34.09	275.79	25.40
Price / Sales	0.25	4.98	695.58	114.44
Price / Cash	2.33	123.23	77.42	51.66
Price / Book	-0.97	5.30	10.46	6.33
Net Income	$27.05M	$313.45M	$3.49B	$358.33M
7 Day Performance	2.26%	1.65%	0.59%	1.12%
1 Month Performance	N/A	-0.98%	-2.01%	-2.67%
1 Year Performance	-56.96%	15.82%	18.09%	6.01%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	4.1288 of 5 stars	$1.36 +0.7%	$2.50 +83.8%	-59.6%	$48.50M	$192.22M	12.36	223	News Coverage
XGN Exagen	3.4663 of 5 stars	$7.49 +1.9%	$9.63 +28.5%	-12.8%	$181.45M	$71.12M	N/A	220
LFMD LifeMD	2.6016 of 5 stars	$3.40 -1.2%	$7.57 +122.7%	-49.9%	$163.88M	$191.59M	N/A	384	News Coverage Analyst Forecast
JYNT Joint	2.3274 of 5 stars	$8.47 +2.0%	N/A	-17.7%	$119.77M	$54.90M	31.37	320	Positive News Analyst Downgrade
PARK Park Dental Partners	4.0351 of 5 stars	$20.71 -2.4%	$28.50 +37.6%	N/A	$98.58M	$244.49M	19.72	1,212	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors